Initial Moon Shots
Related story: MD Anderson's Moon Shots Program
- John Heymach, M.D., Ph.D., associate professor, Department of Thoracic/Head and Neck Medical Oncology
- Stephen Swisher, M.D., chair and professor, Department of Thoracic and Cardiovascular Surgery; head ad interim, Division of Surgery
- Integrate new blood test and novel imaging methods to improve the early detection of lung cancer.
- Complete real-time profiling of all known DNA mutations in 1,000 lung cancer patients.
- Improve specificity of early lung cancer detection by 20% in three years.
- Develop personalized clinical trials tailored to all of the major molecular subtypes of lung cancer.
- Jeffrey Gershenwald, M.D., professor, Department of Surgical Oncology
- Michael Davies, M.D., Ph.D., assistant professor, Department of Melanoma Medical Oncology
- Building upon recent advances, comprehensively profile — both molecularly and immunologically — metastatic melanoma patients to develop and select optimized, personalized therapeutic approaches, unleashing the power of the immune system.
- Exploit molecular insights to develop markers that will guide therapy selection for all melanoma patients.
- Develop personalized therapeutic combinations that will markedly increase the long-term survival rate for patients with metastatic melanoma.
Myelodysplastic syndrome and acute myeloid leukemia
- Guillermo Garcia-Manero, M.D., professor, Department of Leukemia
- Hagop Kantarjian, M.D., chair and professor, Department of Leukemia
- Harness the depth and breadth of targeted therapy programs across many drug classes that target cancer-signaling aberrations, activate immune system responses and enhance anticancer stem cell therapies — all in powerful combinations informed by full sequencing of every MDS and AML patient before and after start of treatment.
- Identify the causes of resistance to treatment and translate that knowledge into significant cure rates for older patients with MDS and AML within five years.
Chronic lymphocytic leukemia
- Michael Keating, M.B., B.S., professor, Department of Leukemia
- William Plunkett, Ph.D., professor, Department of Experimental Therapeutics
- Apply new breakthrough treatments based on specific targeted inhibitors of CLL pathways without damaging DNA or the immune system.
- Replace standard chemotherapy regimens for all patients within one year. Longer-term metric: Double the cure rate of CLL, halve the rate of secondary cancers.
- Christopher Logothetis, M.D., chair and professor, Department of Genitourinary Medical Oncology
- Timothy Thompson, Ph.D., professor, Department of Genitourinary Oncology
- Establish metabolites and metabolic signatures associated with androgen-responsive prostate cancer and castrate-resistant prostate cancer in human tissue samples for the development of clinical prognostic, predictive and/or monitoring biomarkers.
- Develop metabolomics-based biomarkers to monitor response to androgen-deprivation therapy and the transition to castrate-resistant prostate cancer in individual patients, optimizing the use of newly developed therapeutic agents to extend survival of patients with advanced prostate cancer.
Breast and ovarian
- Gordon Mills, M.D., Ph.D., chair and professor, Department of Systems Biology
- Mien-Chie Hung, Ph.D., chair and professor, Department of Molecular and Cellular Oncology
- Anil Sood, M.D., professor, Department of Gynecologic Oncology and Reproductive Medicine and Department of Cancer Biology
Novel project: Transform and individualize therapy for the most dangerous forms of breast and ovarian cancers through discovery and bypass of tumor adaptation and resistance to treatment.
Sample metric: Develop a universal genetic/biomarker test for marker-guided therapy for triple-negative breast cancer and high-grade serous ovarian cancer patients within five years.